LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Search

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

209.2 -0.08

Resumen

Variación precio

24h

Actual

Mínimo

204.77

Máximo

211.44

Métricas clave

By Trading Economics

Ingresos

-22M

-61M

Ventas

56M

214M

Margen de beneficio

-28.549

Empleados

1,017

EBITDA

-56M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+25.78% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.2B

13B

Apertura anterior

209.28

Cierre anterior

209.2

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

166 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 dic 2025, 23:54 UTC

Principales Movimientos del Mercado

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dic 2025, 19:08 UTC

Adquisiciones, fusiones, absorciones

Correction to Alphabet to Buy Intersect Article

22 dic 2025, 17:21 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dic 2025, 16:46 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dic 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dic 2025, 23:42 UTC

Charlas de Mercado

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dic 2025, 22:31 UTC

Ganancias

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dic 2025, 22:31 UTC

Ganancias

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dic 2025, 22:30 UTC

Ganancias

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 dic 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

22 dic 2025, 21:37 UTC

Adquisiciones, fusiones, absorciones

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dic 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dic 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dic 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dic 2025, 20:54 UTC

Adquisiciones, fusiones, absorciones

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dic 2025, 20:52 UTC

Adquisiciones, fusiones, absorciones

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dic 2025, 20:09 UTC

Charlas de Mercado

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dic 2025, 19:56 UTC

Charlas de Mercado

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dic 2025, 19:49 UTC

Adquisiciones, fusiones, absorciones

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dic 2025, 19:23 UTC

Charlas de Mercado

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dic 2025, 19:23 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 dic 2025, 19:02 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

22 dic 2025, 19:02 UTC

Charlas de Mercado

Precious Metals Climb to New Heights -- Market Talk

22 dic 2025, 18:45 UTC

Charlas de Mercado

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dic 2025, 18:30 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dic 2025, 18:23 UTC

Adquisiciones, fusiones, absorciones

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dic 2025, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

22 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

22 dic 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

25.78% repunte

Estimación a 12 meses

Media 263.42 USD  25.78%

Máximo 325 USD

Mínimo 220 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

13

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

166 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat